학술논문
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial.
Document Type
Article
Author
Source
Subject
*METHADONE treatment programs
*SUBSTANCE abuse risk factors
*CLINICAL drug trials
*SUBSTANCE abuse
*PATIENT compliance
*COMBINATION drug therapy
*RISK assessment
*SELF-evaluation
*SECONDARY analysis
*RESEARCH funding
*SEVERITY of illness index
*TREATMENT effectiveness
*DESCRIPTIVE statistics
*NARCOTICS
*DRUGS
*NALOXONE
*COMPARATIVE studies
*PSYCHOLOGICAL tests
*MENTAL depression
*BUPRENORPHINE
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1550-4263
Abstract
To evaluate the impact of depressive symptom severity on opioid use and treatment retention in individuals with prescription-type opioid use disorder (POUD). We analyzed data from a multi-centric, pragmatic, open-label, randomized controlled trial comparing buprenorphine/naloxone to methadone models of care in 272 individuals with POUD. Opioid use was self-reported every two weeks for 24 weeks using the Timeline Followback. Depressive symptom severity was self-reported with the Beck Depression Inventory at baseline, week 12 and week 24. Baseline depressive symptom severity was not associated with opioid use nor treatment retention. At week 12, moderate depressive symptoms were associated with greater opioid use while mild to severe depressive symptoms were associated with lowered treatment retention. At week 24, moderate depressive symptoms were associated with greater opioid use. Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment. [ABSTRACT FROM AUTHOR]